Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) more than halved their risk of dying or developing distant metastasis when treated with darolutamide in addition to androgen deprivation therapy (ADT), according to findings of the phase III ARAMIS* trial.
Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.
The combination of pembrolizumab and axitinib in the first-line setting yielded superior survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to results of the phase III KEYNOTE-426* trial.
The experimental drug vofatamab, a fibroblast growth factor receptor 3 (FGFR3) targeted antibody, exhibited a favourable safety profile when used alone or in combination with the chemotherapeutic agent docetaxel in patients with metastatic urothelial carcinoma (mUC), according to the results of the FIERCE-21* trial presented at ASCO GU 2019.
The biochemically potent, highly selective VEGFR TKI* tivozanib trumped sorafenib in improving progression-free survival (PFS) and objective response rate (ORR) in patients with refractory advanced renal cell carcinoma (RCC), according to results of the TIVO-3** study presented at ASCO GU 2019.
A combination therapy of nivolumab plus ipilimumab (NIVO + IPI) continues to confer survival benefit and durable response over 30 months of follow-up compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to updated results of CheckMate 214 presented at ASCO Genitourinary Cancers Symposium (GUCS) 2019.
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.